Ignite Creation Date:
2024-05-06 @ 6:04 PM
Last Modification Date:
2024-10-26 @ 2:41 PM
Study NCT ID:
NCT05531552
Status:
COMPLETED
Last Update Posted:
2023-07-27
First Post:
2022-08-30
Brief Title:
The Role of Clinical Pharmacist in Monitoring Drug Therapy in the Cardiovascular and Coronary Care Units in Libya
Sponsor:
Beni-Suef University
Organization:
Beni-Suef University
Study Overview
Official Title:
The Role of Clinical Pharmacist in Monitoring Drug Therapy in the Cardiovascular and Coronary Care Units in Libya
Status:
COMPLETED
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BSU
Brief Summary:
Assessment of role of clinical pharmacist in decreasing morbidity and mortality among coronary artery disease patients
Detailed Description:
- Methodology Follow-up patients from A to Z and their risk factors in all phases of disease CAD in groups with advised patients to lose weight decrease smoking and take medication on time
Monitoring drugs to CAD by studying its Pharmacodynamic
Mechanism of action therapeutic uses indication adverse effect and suitable doses and drug-drug interactions and contraindications
The study shows the Compare between the patients in Medical Center Hospital with and without guidelines of clinical pharmacy Were managed all by setting a plan with the cardiologist in Libya
Follow-up was for the one hundred patients in the three groups Outpatient Inpatient and the patients in Cardio Care Unit - CCU
First subgroup Outpatient monitored the drugs used in HTN DM and Hyperlipidemia dyslipidemia to decrease levels of patients who come to the hospital with IHD therefore reduce morbidity Also it was followed by measurement of BP twice weekly test for Blood sugar glucose level once monthly and tests the Low-Density Lipoprotein LDL at the cardiologists request
Second subgroup Inpatient monitored drugs according to international guidelines of clinical pharmacy to decrease the medication errors and management of the drug of stable angina and protected patients from increasing the problem myocardial infarction and reduce rates of entry to CCU
Third subgroup Patients in CCU Practiced the international roles of clinical pharmacy to monitor drug use to unstable Angina and MI to decrease mortality in Libya
Method of analysis
Were monitored one hundred patients and divided into
Twenty patients from outpatient divided to 10pts-10pts Ten patients was written the data collected in accordance with the system adopted at the Medical Center Hospital
Ten patientsThey are patients who applied the guidelines of clinical pharmacy to them in Medical Center Hospital by recommending cardiologists practice the clinical pharmacy guidelines and tailoring doses
50 of inpatients as outpatient 25pts-25pts
30 patients in CCU divided into 15pts-15pts
- The statistical analysis was the comparison between the two groups
The first group of patients was undergoing treatment in the Medical Center Hospital without applying guidelines 10 patients-25pts-15pts
The second group are a group of patients undergoing treatment in the Medical Center Hospital in accordance with guidelines 10pts-25pts-15pts
The comparison was in terms of the rate of survival the speed of symmetry to heal ie responsiveness to medications the rate of complications and death for both groups
- The purpose of this review is to summarize the role of clinical pharmacy benefits in all aspects of cardiovascular diseases CVD in hospitalized patients
Managed the risk factors hypertension diabetes dyslipidemia and Ischemic heart disease by monitoring the common drugs in Libya
Diuretics ACEIs and ARBs for hypertension
Insulin and Biguanides Metformin for diabetes
Statins for dyslipidemia
Organic nitrates CCB BB Antiplatelets Anticoagulant and Fibrinolytics for ischemic heart disease
And the summary of the aim of the work is the practice of guidelines of clinical pharmacy to manage coronary artery disease to reduce levels of morbidity and mortality in Libya and to prove the need for the presence of clinical pharmacists in Libyan hospitals
Monitoring drugs to CAD by studying its Pharmacodynamic
Mechanism of action therapeutic uses indication adverse effect and suitable doses and drug-drug interactions and contraindications
The study shows the Compare between the patients in Medical Center Hospital with and without guidelines of clinical pharmacy Were managed all by setting a plan with the cardiologist in Libya
Follow-up was for the one hundred patients in the three groups Outpatient Inpatient and the patients in Cardio Care Unit - CCU
First subgroup Outpatient monitored the drugs used in HTN DM and Hyperlipidemia dyslipidemia to decrease levels of patients who come to the hospital with IHD therefore reduce morbidity Also it was followed by measurement of BP twice weekly test for Blood sugar glucose level once monthly and tests the Low-Density Lipoprotein LDL at the cardiologists request
Second subgroup Inpatient monitored drugs according to international guidelines of clinical pharmacy to decrease the medication errors and management of the drug of stable angina and protected patients from increasing the problem myocardial infarction and reduce rates of entry to CCU
Third subgroup Patients in CCU Practiced the international roles of clinical pharmacy to monitor drug use to unstable Angina and MI to decrease mortality in Libya
Method of analysis
Were monitored one hundred patients and divided into
Twenty patients from outpatient divided to 10pts-10pts Ten patients was written the data collected in accordance with the system adopted at the Medical Center Hospital
Ten patientsThey are patients who applied the guidelines of clinical pharmacy to them in Medical Center Hospital by recommending cardiologists practice the clinical pharmacy guidelines and tailoring doses
50 of inpatients as outpatient 25pts-25pts
30 patients in CCU divided into 15pts-15pts
- The statistical analysis was the comparison between the two groups
The first group of patients was undergoing treatment in the Medical Center Hospital without applying guidelines 10 patients-25pts-15pts
The second group are a group of patients undergoing treatment in the Medical Center Hospital in accordance with guidelines 10pts-25pts-15pts
The comparison was in terms of the rate of survival the speed of symmetry to heal ie responsiveness to medications the rate of complications and death for both groups
- The purpose of this review is to summarize the role of clinical pharmacy benefits in all aspects of cardiovascular diseases CVD in hospitalized patients
Managed the risk factors hypertension diabetes dyslipidemia and Ischemic heart disease by monitoring the common drugs in Libya
Diuretics ACEIs and ARBs for hypertension
Insulin and Biguanides Metformin for diabetes
Statins for dyslipidemia
Organic nitrates CCB BB Antiplatelets Anticoagulant and Fibrinolytics for ischemic heart disease
And the summary of the aim of the work is the practice of guidelines of clinical pharmacy to manage coronary artery disease to reduce levels of morbidity and mortality in Libya and to prove the need for the presence of clinical pharmacists in Libyan hospitals
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None